Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

Model scores of the 29,894 trials active now.

Model score 21% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (1,598 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-11-26. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 17.2% (raises risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: chemotherapycarboplatinamlleukemiacancer
  Phrases that lowered it: participantparticipantsmkmoderatestart of
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 124 (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor's past trials: 1265 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, dermatology: Yes (raises risk) · Disease area
• Drug's FAERS reports in the prior 12 months: 21460 (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Drugs with FDA adverse-event history: 4 (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 109947 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Collaborators: 0 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) NCT02819518 · started 2016 · scored riskier than 49% of active trials completed
• Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer NCT02766582 · started 2016 · scored riskier than 97% of active trials completed
• Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) NCT02578680 · started 2016 · scored riskier than 40% of active trials completed
• Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086) NCT02447003 · started 2015 · scored riskier than 46% of active trials completed
• Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) NCT03396445 · started 2018 · scored riskier than 30% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.